P272 A 7 year retrospective evaluation of initiation of long term non-invasive ventilatory support for motor neurone disease

    loading  Checking for direct PDF access through Ovid


In 2010 NICE (1) published it's guideline for the use of non-invasive ventilation in the management of motor neurone disease (MND). We have offered long-term non-invasive ventilation (NIV) in this patient group for7 years. We have evaluated concordance data for all patients set-up during this time.


Data were obtained by retrospective case-note review of all patients set-up on NIV for MND between April 2004 and March 2011inclusive.


42 patients were set-up over 7 years. Mean length of time from diagnosis to ventilation was 13.9 months, with three patients being set-up on diagnosis and a further three before diagnosis. 69% (n=29) were set-up at home, the remainder in hospital. 71% (n=30) of those set up were eventually concordant, 19% (n=8) did not tolerate NIV, while 10% (n=4) died during initiation. Those set-up in hospital had a tendency to be more concordant with ventilation than those set-up at home (76% vs 69%). This group also became concordant more rapidly (4.4 days vs 14.2 days). Those with both symptomatic and physiological indications for ventilation appeared to tolerate it extremely well with 84% (n=24) becoming concordant. There was a failure rate of 75% of those with physiological indications only. Of those with symptoms only and no apparent abnormal physiological markers 80% (n=4) complied with treatment. Symptomatically daytime somnolence was the most commonly reported symptom, with 81% (n=34) of patients being sleepy by day. Nocturia was the least commonly reported at 11%. In terms of mortality, mean survival from initiation to death was 10.2 months (range 0.67–84). In total three patients progressed from NIV to tracheostomy ventilation, one of these survived a further 5 years.


Those with MND have a tendency to have better concordance with NIV if started in hospital rather than at home; concordance also appears to be more rapid in this group. As expected, given the nature of this treatment those without symptoms tend not to tolerate NIV.

Related Topics

    loading  Loading Related Articles